Key Takeaways
Drawing from SVB’s proprietary data and insights, and interviews with prominent investors and founders, our 2026 Innovation in Women’s Health report examines trends across the venture-backed women’s health sector, which has expanded well beyond reproductive and sexual health to address the full spectrum of women’s health needs. Now a proving ground for the future of medicine, the sector is pioneering advances in integrated care, personalization and technology that are setting new standards of care for all patients.
$2B VC invested in women’s health across the US and Europe in 2025.
While this marked a dip from the 2024 peak, projections show a rebound in both deal volume and total women’s health funding for 2026.
$6.2B VC invested since 2019 in companies addressing conditions unique to women.
Plus 210 new startups dedicated to solving women-specific health challenges have launched in the same timeframe.
$35M Median pre-money valuation for AI-enabled women’s health companies.
Startups using AI to personalize care are commanding valuations triple those of their non-AI counterparts.
A 2025 dip gives way to a stronger 2026
US women’s health VC saw a $1.2B pullback in 2025, but early indications suggest a rebound in 2026 as a new wave of seed and Series A companies prepares to emerge.
The dip reflects the sector’s focus on therapeutics and care delivery, making it less susceptible to the AI investment hype in 2024 that inflated other healthcare verticals – and setting the stage for more stable, long-term growth.
Notes: All deals either include institutional venture investment, corporate venture investment or are equal to or greater than $2M, regardless of investor. Dates of financing rounds are subject to change based on add-on investments. The projection for 2026 is based on identified women's health companies which raised a deal as of 5/15/2026 along with new deals for additional companies identified through Pitchbook industry tagging.
Source: PitchBook Data, Inc. and SVB proprietary data and analysis.
Investors triple down on women’s health AI
Valuations for AI-powered women’s health companies were nearly 3x the sector median, a sharp departure from prior years when little difference existed between them.
Women’s health AI investment is concentrated in clinical tools that predict and prevent costly health events like hospitalization and serious illness, rather than the drug discovery and operations focus in broader healthcare AI.
Investment aligns with shared disease burden
Diseases with high patient populations and low investment tend to attract VC funding. As a result, major women’s health concerns tend to attract more money if they impact men as well.
This focus means women’s health companies are helping to prove the value of personalized and precision medicine in a broader set of conditions that affect a variety of patients.
Explore other SVB reports
Written and researched by SVB experts
Our deep relationships with top entrepreneurs and investors inform our insights and give us a vantage point unlike any other bank.
